Guideline on Labelling and Package Leaflet of Centrally Authorised Medicinal Products Updated
Recommendation
Wednesday, 21 May 2025 10.00 - 16.00 h
How to use and prepare an MA with a CEP 2.0
Register now for ECA's GMP Newsletter
The Guideline of the EC Commission entitled "Guideline on the packaging information of medicinal products for human use authorised by the Union" is part of EudraLex's "Notice of Applicants; Volume 2C - Regulatory Guidelines" and contains requirements for designing the labelling and package leaflets of centrally authorised medicinal products. The Guideline has been recently released after a radical revision (Revision 14). It now contains many changes and amendments to the previous version 13 from February 2008. The annex with country specific requirements already provides information regarding Croatia, EU's most recent Member State.
Mainly the provisions from the new Regulation (EU) No 1027/2012 on Pharmacovigilance legislation and Directive 2012/26/EU (both dated 25 October 2012) have been integrated into the revised Guideline.
The changes made to the new document can be clearly identified in a comparative document. This comparison is available for ECA members in the ECA members' area.
Related GMP News
16.04.2025EMA: Revised IRIS Documents
09.04.2025Centralised Procedures: Q&As Updated
12.03.2025CMDh/HMA: Guidance Documents on Variation Notifications Updated
11.03.2025EMA: Renewal of Q&A Document for "Centralized Procedures"
11.03.2025Centralised Procedures: Q&A Documents also Updated for Biosimilars
29.01.2025CMDh/HMA: Updated Guidance Documents on Variation Notifications